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Abstract
Background: To determine short‐ and long‐term oncologic outcomes after minimally
invasive distal pancreatectomy (MIDP) with open distal pancreatectomy (ODP) for
the treatment of pancreatic neuroendocrine tumor (pNET).
Methods: The data of the patients who underwent curative MIDP or ODP for pNET
between 2000 and 2016 were collected from a multi‐institutional database.
Propensity score matching (PSM) was used to generate 1:1 matched patients with
MIDP and ODP.
Results: A total of 576 patients undergoing curative DP for pNET were included.
Two hundred and fourteen (37.2%) patients underwent MIDP, whereas 362
(62.8%) underwent ODP. MIDP was increasingly performed over time (2000‐
2004: 9.3% vs 2013‐2016: 54.8%; P < 0.01). In the matched cohort (n = 141 in
each group), patients who underwent MIDP had less blood loss (median, 100 vs
200 mL, P < 0.001), lower incidence of Clavien‐Dindo ≥ III complications (12.1% vs
24.8%, P = 0.026), and a shorter hospital stay versus ODP (median, 4 versus 7 days,
P = 0.026). Patients who underwent MIDP had a lower incidence of recurrence
(5‐year cumulative recurrence, 10.1% vs 31.1%, P < 0.001), yet equivalent overall
survival (OS) rate (5‐year OS, 92.1% vs 90.9%, P = 0.550) compared with patients
who underwent OPD.
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Conclusion: Patients undergoing MIDP over ODP in the treatment of pNET had
comparable oncologic surgical metrics, as well as similar long‐term OS.
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1 | INTRODUCTION
Pancreatic neuroendocrine tumors (pNET) account for 2% to 4%
of all pancreatic neoplasms diagnosed in the general population.1,2
Over the last two decades, the incidence of pNET has increased
significantly because of the widespread use of cross‐sectional
imaging.3 In fact, the incidence of pNET currently is about 0.48
per 100,000 persons and pNET is the leading cause of cancer‐
related deaths in the United States.4,5 Although most cases are
sporadic, 10%‐30% are associated with genetic syndromes,
such as multiple endocrine neoplasia 1 syndrome, and Von
Hippel‐Lindau disease.1,2
Surgical resection remains the optimal curative modality for
pNET and is the treatment of choice even among certain patients
with locally advanced or metastatic disease.6-9 The surgical
approach can consist of “typical” and “atypical” resections
depending on the number, size, and location of the tumor(s).
Typical resection includes pancreaticoduodenectomy (PD) for
tumors located in the pancreatic head, distal pancreatectomy
(DP) for tumors located in the body and tail, and rarely total
pancreatectomy (TP) when tumors spread within the whole
gland.3,10 Atypical resection includes enucleation and central
pancreatectomy (CP) and is more often utilized when tumors are
small (<2‐3 cm), benign, well‐circumscribed, as well as not adjacent
to the duct of Wirsung so that the duct can remain intact after
tumor resection.10,11
Because the first laparoscopic pancreatic surgery performed
by Cuschieri in 1994,12 laparoscopic surgery has been increasingly
utilized in pancreatic surgery because of its minimal invasiveness
versus open procedures.3,13-16 Because of its overall relatively low
incidence, the assessment of short‐ and long‐term outcomes after
laparoscopic versus open surgery for pNET have been limited.
Especially, most data have been derived from small retrospective
studies that have yielded disparate results.3,10,15,16 In addition, the
heterogeneity of patients who had different tumor locations
requiring different surgical procedures may induce selection bias
when comparing minimally invasive versus open surgical ap-
proaches. In addition, most previous studies largely focused on
short‐term outcomes with the long‐term oncological outcomes of
minimally invasive vs open surgery for pNETs remaining largely
undetermined.10 Therefore, the objective of the current study was
to define short‐ and long‐term outcomes after minimally invasive
distal pancreatectomy (MIDP) vs open distal pancreatectomy
(ODP) among patients with pNETs located in the body and tail of
the pancreas.
2 | PATIENTS AND METHODS
2.1 | Design and patients
Patients who underwent curative resection for pNET between 2000
and 2016 were identified from the U.S. Neuroendocrine Tumor Study
Group (US‐NETSG). The US‐NETSG included The Ohio State
University Wexner Medical Center and James Comprehensive
Cancer Center, Columbus, OH; Winship Cancer Institute, Emory
University, Atlanta, GA; Stanford University, Palo Alto, CA; Virginia
Mason Medical Center, Seattle, WA; University of Wisconsin, School
of Medicine and Public Health, Madison, WI; Washington University,
School of Medicine, St. Louis, MO; Vanderbilt University, Nashville,
TN; University of Michigan, Ann Arbor, MI.17 The Institutional
Review Board of each participating institution approved the study.
All patients were pathologically diagnosed with pNET on the
basis of conventional histology and immunohistochemical findings
(chromogranin A, synaptophysin, and Ki‐67). Standard patient
demographic, clinicopathologic, and perioperative data were
collected on the basis of a prospectively maintained database.
2.2 | Surgical treatment and postoperative
surveillance
All surgeries were performed by specialized physicians. Choice of
laparoscopic/robotic or open surgery was mostly determined by
tumor factors, as well as surgeon preference. Operative time was
defined as the time duration between the first incision and skin
closure. Margin status was determined by the pathologist on the
basis of the examination of all specimen margin sites on permanent
sections. An R0 resection was defined as a minimum margin length of
>1mm; the microscopic presence of the tumor at the margin or a
minimum margin length of ≤1mm was designated as an R1 resection.
The inability to resect all gross residual disease was defined as an R2
resection.18 Tumor‐related characteristics, including maximal tumor
diameter, number, location, tumor morphology, histological grade,
lymph‐vascular/perineural invasion, Ki‐67, mitotic rate, nodal status
were recorded on the basis of final pathology. All cases were
reviewed and classified according to the World Health Organization
(WHO) criteria.19
Postoperative morbidity was graded according to the Clavien‐
Dindo classification.20 The definition of postoperative hemorrhage
and the pancreatic fistula was on the basis of the International Study
Group of Pancreatic Surgery.21,22 All patients were followed
regularly in each participating institution. Disease recurrence was
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defined as identification of suspicious imaging findings on post-
operative surveillance or biopsy‐proven recurrent pNET. Overall
survival (OS) was calculated from the date of surgery to the date of
death or date of last follow‐up.
2.3 | Statistical analysis
Numerical variables were expressed as medians with interquartile
ranges (IQR) and compared with Student t test or the Mann‐Whitney
U test between the two groups. Nominal variables were expressed as
number and percentages and compared with the Chi‐squared test or
Fisher's exact test. Survival probabilities were estimated by Kaplan‐
Meier methodology and compared by log‐rank analysis. Two‐tailed
P‐values < 0.05 were considered statistically significant. Potential risk
factors associated with OS and tumor recurrence were identified
using univariate and multivariable Cox hazard regression models.
Results were reported as hazard ratios (HR) and 95% confidence
intervals (95% CI). Propensity score matching (PSM) was used to
mitigate selection bias. Specifically, variables potentially affecting
long‐term outcomes were utilized in the propensity score on the
basis of identification in the logistic regression analysis. The
propensity score analysis with 1:1 matching was performed without
replacement using a caliper with a width 0.05 of the standard
deviation to generate matched pairs of the patients. In all analyses,
two‐tailed P value < 0.05 was considered statistically significant.
Statistical analysis was carried out using SPSS 22.0 (Chicago, IL).
3 | RESULTS
A total of 1020 patients undergoing curative‐intent resection for
pNET were included (Figure 1). Classic PD was performed in 129
patients, pylorus‐preserving pancreaticoduodenectomy (PPPD) in
159 patients, CP in 32 patients, DP in 576 patients, TP in 17
patients, and tumor enucleation in 107 patients. Minimally invasive
surgery (MIS) was mainly performed among patients undergoing DP;
214 patients who underwent MIDP, 25 patients who underwent
laparoscopic/robotic converted to ODP, and 337 patients who
underwent ODP were included in the analytic cohort. Utilization of
MIDP increased over time (2000‐2004, 9.3%; 2005‐2008, 14.5%;
2009‐2012, 41.8%; 2013‐2016, 54.8%, P < 0.01 for trend; Figure 2).
In addition, the conversion rate of MIDP to open decreased (2000‐
2004, 20.0%; 2005‐2008, 29.6%, 2009‐2012, 7.8%, 2013‐2016, 7.6%;
Table S1).
3.1 | Analytic cohort
Among the 576 patients who underwent curative DP for pNET,
median age was 58 (IQR 48‐66) years with a slight female
predominance (n = 314, 54.5%). A majority of patients (n = 490,
85.1%) presented with nonfunctional tumors and had no specific
genetic syndrome (n = 512, 88.9%); almost half of patients
(n = 276, 47.9%) were symptomatic. Most patients had a single
(n = 510, 88.5%), small ( ≤ 3 cm, n = 375, 65.1%) mass and a well‐
differentiated tumor (n = 443, 76.9%). Most tumors (n = 386,
67.0%) were located in the pancreatic tail. After the surgery,
roughly one‐half of patients (n = 304, 52.8%) experienced at least
one complication, whereas 113 (19.6%) patients experienced a
severe complication (Clavien‐Dindo III‐V); 22 (3.8%) patients
required reoperation because of bleeding (n = 9), intra‐abdominal
abscess (n = 6), intestinal obstruction (n = 3), and unknown reasons
(n = 4; Table 1).
F IGURE 1 Study scenario and patient
selection. CP, central pancreatectomy; DP,
distal pancreatectomy; MIS, minimally
invasive surgery; PD,
pancreaticoduodenectomy; PNET,
pancreatic neuroendocrine tumor; PPPD,
pylorus‐preserving
pancreaticoduodenectomy; TP, total
pancreatectomy
F IGURE 2 Utilization of minimally invasive distal pancreatectomy
(MIDP) and open distal pancreatectomy (ODP) for pancreatic
neuroendocrine tumor (pNET) at different time periods
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TABLE 1 Clinicopathologic characteristics and operation details of patients undergoing minimally invasive distal pancreatectomy (MIDP)
versus open distal pancreatectomy (ODP) for pancreatic neuroendocrine tumors (pNETs)
Overall
(n = 576) MIDP (n = 214) ODP (n = 362) P value
Age, y 58 (48‐66) 59 (50‐66) 56 (47‐65) 0.414
Sex 0.489
Male 262 (45.5%) 93 (43.5%) 169 (46.7%)
Female 314 (54.5%) 121 (56.5%) 193 (53.3%)
BMI, kg/m2 28.4 (25.3‐34.0) 29.2 (25.9‐33.8) 28.2 (24.5‐34.3) 0.359
Functional status 0.245
Nonfunctional 490 (85.1%) 179 (83.6%) 311 (85.9%)
Functional 73 (12.7%) 32 (15.0%) 41 (11.3%)
NA 13 (2.3%) 3 (1.4%) 10 (2.8%)
Genetic syndrome 0.064
None 512 (88.9%) 199 (93.0%) 313 (86.5%)
MEN 1 50 (8.7%) 12 (5.6%) 38 (10.5%)
VHL 2 (0.3%) 0 2 (0.6%)
NA 12 (2.1%) 3 (1.4%) 9 (2.5%)
Symptomatic 276 (47.9%) 99 (46.3%) 177 (48.9%) 0.486
Primary location <0.001
Neck/body 162 (28.1%) 46 (21.5%) 116 (32.0%)
Tail 386 (67.0%) 165 (77.1%) 221 (61.0%)
Multiple location 28 (4.9%) 3 (1.4%) 25 (6.9%)
Largest tumor size, cm 0.001
≤3 375 (65.1%) 157 (73.4%) 218 (60.2%)
>3 180 (31.3%) 49 (22.9%) 131 (36.2%)
Tumor number 0.002
Single 510 (88.5%) 201 (93.9%) 309 (85.4%)
multiple 66 (11.5%) 13 (6.1%) 53 (14.6%)
Splenectomy 477 (82.8%) 162 (75.7%) 315 (87.0%) 0.001
Additional enucleation 16 (2.8%) 1 (0.5%) 15 (4.1%) 0.007
Major vascular resection 11 (1.9%) 0 11 (3.0%) 0.009
Pancreatic transection <0.001
Hand‐sewn 30 (5.2%) 3 (1.4%) 27 (7.5%)
Stapled with no suture 220 (38.2%) 113 (52.8%) 107 (29.6%)
Stapled with reinforcement 160 (27.8%) 49 (22.9%) 111 (30.6%)
Other procedures 23 (4.0%) 7 (3.3%) 16 (4.4%)
Missing 143 (24.8%) 42 (19.6%) 101 (27.9%)
Intraoperative abdominal drainage 518 (89.9%) 189 (88.3%) 329 (90.9%) 0.132
Operation time, min 210 (179‐263) 210 (180‐258) 210 (177‐266) 0.652
Estimated blood loss, mL 200 (100‐400) 100 (50‐150) 300 (150‐500) <0.001
Lymphadenectomy 509 (88.4%) 187 (87.4%) 322 (89.0%) 0.331
No. of lymph node retrieved 9 (4‐14) 9 (4‐14) 8 (4‐14) 0.709
Lymph nodes status 0.001
Negative 411 (71.4%) 166 (77.6%) 245 (67.7%)
Positive 99 (17.2%) 22 (10.3%) 77 (21.3%)
Tumor differentiation 0.824
Well differentiated 443 (76.9%) 173 (80.8%) 270 (74.6%)
Moderately differentiated 53 (9.2%) 23 (10.7%) 30 (8.3%)
(Continues)
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TABLE 1 (Continued)
Overall
(n = 576) MIDP (n = 214) ODP (n = 362) P value
Poorly differentiated 8 (1.4%) 3 (1.4%) 5 (1.4%)
NA 72 (12.5%) 15 (7.0%) 57 (15.7%)
Margin status 0.005
R0 498 (86.5%) 196 (91.6%) 302 (83.4%)
R1 78 (13.5%) 18 (8.4%) 60 (16.6%)
Ki‐67 0.040
<3% 242 (42.0%) 118 (55.1%) 124 (34.3%)
3%‐20% 141 (24.5%) 50 (23.4%) 91 (25.1%)
>20% 12 (2.1%) 5 (2.3%) 7 (1.9%)
Mitotic rate 0.485
<2 291 (50.5%) 134 (62.6%) 157 (43.4%)
2‐20 57 (9.9%) 23 (10.7%) 34 (9.4%)
>20 1 (0.2%) 0 1 (0.3%)
WHO classification 0.712
G1 304 (52.8%) 124 (57.9%) 180 (49.7%)
G2 138 (24.0%) 53 (24.8%) 85 (23.5%)
G3 13 (2.3%) 4 (1.9%) 9 (2.5%)
Unknown 121 (21.0%) 33 (15.4%) 88 (24.3%)
Lymph‐vascular invasion <0.001
Absent 357 (62.0%) 162 (75.7%) 195 (53.9%)
Present 122 (21.2%) 31 (14.5%) 91 (25.1%)
Perineural invasion 0.065
Absent 360 (62.5%) 155 (72.4%) 205 (56.6%)
Present 71 (12.3%) 22 (10.3%) 49 (13.5%)
Postoperative morbidity 304 (52.8%) 102 (47.7%) 202 (55.8%) 0.046
Clavein‐Dindo classification 0.023
I 83 (14.4%) 39 (18.2%) 44 (12.2%)
II 108 (18.8%) 35 (16.4%) 73 (20.2%)
IIIa 67 (11.6%) 13 (6.1%) 54 (14.9%)
IIIb 15 (2.6%) 4 (1.9%) 11 (3.0%)
IVa 19 (3.3%) 7 (3.3%) 12 (3.3%)
IVb 6 (1.0%) 1 (0.5%) 5 (1.4%)
V 6 (1.0%) 3 (1.4%) 3 (0.8%)
Severe complication, III‐V 113 (19.6%) 28 (13.1%) 85 (23.3%) 0.017
Postoperative hemorrhage 13 (2.3%) 5 (2.3%) 8 (2.2%) 1.000
Pancreatic fistula 0.915
A 88 (15.3%) 31 (14.5%) 57 (15.7%)
B 57 (9.9%) 20 (9.3%) 37 (10.2%)
C 4 (0.7%) 1 (0.5%) 3 (0.8%)
Wound infection 27 (4.7%) 5 (2.3%) 22 (6.1%) 0.042
Wound disruption 11 (1.9%) 2 (0.9%) 9 (2.5%) 0.225
Intra‐abdominal infection 64 (11.1%) 16 (7.5%) 48 (13.3%) 0.038
Postoperative drainage 74 (12.8%) 16 (7.5%) 58 (16.0%) 0.003
Length of stay, d 6 (5‐8) 5 (4‐6) 7 (5‐9) 0.007
Reoperation 22 (3.8%) 7 (3.3%) 15 (4.1%) 0.659
Abbreviations: MEN, multiple endocrine neoplasia; MIDP, minimally invasive distal pancreatectomy; ODP, open distal pancreatectomy;
VHL, Von Hippel‐Lindau.
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The clinicopathologic characteristics and surgical details among
patients undergoing MIDP (n = 214, 37.2%) and ODP (n = 362, 62.8%)
were assessed (Table 1). Compared with OPD, MIDP was more likely
to be performed among patients with a single (MIDP 93.9% vs OPD
85.4%, P = 0.002) smaller tumor (≤3 cm, MIDP 73.4% vs OPD 60.2%,
P = 0.001). In addition, concomitant splenectomy (MIDP 75.7% vs
OPD 87.0%, P = 0.001) and additional pancreatic enucleation (MIDP
0.5% vs OPD 4.1%, P = 0.002) were less frequently performed among
patients undergoing MIDP vs OPD. MIDP was associated with less
intraoperative blood loss than OPD (median, 100 versus 300mL,
P < 0.001), yet operative time (median, 210minutes versus 210), as
well as final WHO classification and tumor grade were similar among
patients undergoing MIDP vs OPD (all P > 0.05). The number of
lymph node retrieved (median, 9 vs 8, P = 0.709) were equivalent
among MIDP and OPD. Interestingly, the median number of lymph
nodes harvested increased over time among patients undergoing
both MIDP (2000‐2004, 3 nodes vs 2013‐2016, 10 nodes) and OPD
(2000‐2004, 3 nodes vs 2013‐2016, 13 nodes; Table S1, both
P < 0.05). In contrast, the incidence of R0 resection was higher among
patients undergoing MIDP vs OPD (91.6% vs 83.4%, P = 0.005).
MIDP was also associated with lower overall postoperative morbidity
(47.7% vs 55.8%, P = 0.046), as well as a lower incidence of wound
infection (2.3% vs 6.1%, P = 0.042), severe complications (13.1% vs
23.3%, P = 0.017), and a shorter in‐hospital stay (median 5 days vs 7
days, P = 0.007) vs OPD (Table 1). Of note, while the length‐of‐stay
did not differ over time in the OPD group, the length‐of‐stay did
decrease from a median of 9 days to 4 days in the MIDP group
(Table S1).
3.2 | Long‐term outcomes
With a median follow‐up of 35.4 months (IQR 11.9‐62.0 months), 77
(13.4%) patients developed recurrence (MIDP, 3.7% vs ODP, 19.1%)
and 53 (9.2%) patients died (MIDP, 5.1% vs ODP, 11.6%). Overall 3‐,
5‐, and 10‐year cumulative recurrence was 2.7%, 8.9%, and 8.9%
among patients who had MIDP vs 18.4%, 25.9%, and 42.7% among
individuals who underwent ODP, respectively (HR 0.2, 95% CI,
0.1‐0.5, P < 0.001; Figure 3A). In contrast, OS was comparable among
patients undergoing MIDP and ODP (3‐, 5‐, and 10‐year OS, MIDP
F IGURE 3 Cumulative tumor recurrence rate (A) and overall survival (B) among patients undergoing minimally invasive distal
pancreatectomy (MIDP) and open distal pancreatectomy (ODP) for pancreatic neuroendocrine tumor (pNET) in an unadjusted cohort.
Cumulative tumor recurrence rate (C) and overall survival (D) among patients undergoing MIDP and ODP for pNET in adjusted cohort [Color
figure can be viewed at wileyonlinelibrary.com]
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92.8%, 91.2% and 91.2% vs ODP 94.0%, 90.1%, and 72.9%, P = 0.300;
Figure 3B).
As the baseline characteristics among patients undergoing
MIDP and ODP were different, PSM was utilized to generate 141
pairs of matched patients with similar functional status, tumor
size, number, classification, as well as proportion of splenectomy,
vascular resection, number of lymph node evaluated, number of
metastatic nodes, margin status, and lymph‐vascular invasion
(Table S2). In the propensity model, patients who underwent
MIDP had less blood loss (median, MIDP 100 [105‐500] vs ODP
200 [105‐500] mL, P < 0.001) and a lower incidence of severe
complications (Clavien‐Dindo III‐V; MIDP 12.1% vs ODP
24.8%, P = 0.026), although overall morbidity was equivalent
(Table 2). Perhaps not surprisingly, MIDP remained associated
with a shorter in‐hospital stay vs ODP (median, 44-6 vs 75-9 days,
P = 0.026; Table 2). Of note, in the propensity model, patients who
underwent MIDP had a lower incidence of recurrence (5‐year
cumulative recurrence rate, MIDP 10.1% vs ODP 31.1%, P < 0.001;
Figure 3C), yet comparable OS (5‐year OS, MIDP 92.1% vs ODP
90.9% P = 0.550; Figure 3D). In assessing the entire cohort on the
multivariable analysis, history of a genetic syndrome (HR 2.5,
95% CI, 1.1‐5.8, P = 0.034) and tumor size >3 cm (HR 3.3, 95%
CI, 1.4‐7.4, P = 0.005) were associated with increased risk of tumor
recurrence, whereas MIDP (vs ODP, HR 0.3, 95% CI, 0.1‐0.9,
P = 0.033) was associated with decreased tumor recurrence
(Table 3). While MIDOP vs ODP was not associated with OS,
tumor characteristics, such as WHO G3 classification (ref. G1, HR
4.0, 95% CI, 1.2‐13.2, P = 0.001) and poor tumor differentiation
(ref. well differentiation, HR 2.3, 95% CI, 1.2‐6.7, P = 0.025) were
associated with worse OS (Table S3).
4 | DISCUSSION
While MIS has been increasingly adopted for the treatment of
pancreatic disease, the benefits of MIDP among patients with pNET
remain not well described. The current study was important because,
using a large multi‐institutional cohort, we noted that utilization of
MIDP vs ODP in the treatment of pNET had dramatically increased
over the last two decades in specialized centers throughout the
United States. Perhaps more importantly, the data from the current
study demonstrated the short‐term clinical advantages of MIDP vs
ODP for pNET, including decreased intraoperative blood loss, as well
as less risk of overall and severe postoperative morbidity and a
shorter length of stay. Of note, ODP was more frequently performed
among patients with advanced disease in terms of tumor size,
number, vascular resection, and nodal involvement. As such, patients
who underwent ODP had a higher incidence of tumor recurrence
than patients who underwent MIDP (5‐year cumulative recurrence
rate, ODP 31.1% vs MIDP 10.1%, P < 0.001). However, on both PSM
and multivariate analysis, after controlling for some of these
disparate risk factors, OS was equivalent among patients who
underwent MIDP vs ODP.
The short‐term benefits of MIDP vs ODP have been a topic
of much interest. One systemic review and meta‐analysis that
included a total of 907 patients from eleven studies demonstrated
comparable postoperative morbidity and mortality, as patients
had the same incidence of pancreatic fistula, tumor recurrence, and
postoperative mortality.3 MIDP was associated, however, with a
shorter hospital stay and less blood loss. In contrast, a more recent
meta‐analysis by Drymousis and colleagues reported that patients
who underwent laparoscopic surgery not only had lower blood loss
and a shorter hospital stay but also lower overall morbidity.16 Both of
these previous meta‐analyses suffered, however, from the inclusion
of mostly small single‐center reports that failed to include statistical
methodology, such as PSM to account for the heterogeneity among
patients undergoing different surgical procedures. In contrast, the
current study utilized PSM to help balance the MIDP and ODP
cohorts. Of note, even after PSM, MIDP remained associated with
decreased intraoperative blood loss, lower incidence of postopera-
tive morbidity, and a shorter hospital stay compared with ODP. In
addition, patients who underwent MIDP had a lower incidence of
severe complications. While a previous report reported comparable
postoperative morbidity and mortality between MIDP and ODP, the
TABLE 2 Postoperative morbidity of patients undergoing mini-
mally invasive distal pancreatectomy (MIDP) versus open distal
pancreatectomy (ODP) for pancreatic neuroendocrine tumors
(pNETs) in the propensity model
MIS
(n = 141)
Open
(n = 141) P value
Postoperative morbidity 68 (48.2%) 82 (58.2%) 0.094
Clavein‐Dindo
classification
0.072
I 30 (21.3%) 17 (12.1%)
II 21 (14.9%) 30 (21.3%)
IIIa 9 (6.4%) 20 (14.2%)
IIIb 3 (2.1%) 6 (4.3%)
IVa 4 (2.8%) 5 (3.5%)
IVb 0 2 (1.4%)
V 1 (0.7%) 2 (1.4%)
Severe complication, III‐V 17 (12.1%) 35 (24.8%) 0.026
Postoperative hemorrhage 4 (2.8%) 3 (2.1%) 1.000
Pancreatic fistula 0.651
A 24 (17.0%) 28 (19.9%)
B 15 (10.6%) 14 (9.9%)
C 0 0
Wound infection 1 (0.7%) 5 (3.5%) 0.214
Wound disruption 1 (0.7%) 5 (3.5%) 0.214
Intra‐abdominal infection 8 (5.7%) 14 (9.9%) 0.266
Postoperative drainage 11 (7.8%) 20 (14.2%) 0.090
Length of stay, d 4 (4‐6) 7 (5‐9) 0.026
Reoperation 3 (2.1%) 7 (5.0%) 0.217
Abbreviations: MIS, minimally invasive surgery.
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study had suggested a superiority of MIDP over ODP for pancreatic
ductal adenocarcinoma in terms of intraoperative blood loss and
hospital stay.23 A separate study by Xoufras et al24 that examined
patients who underwent DP for pNET noted that laparoscopic DP
was associated with a lower incidence of postoperative complications
and a shorter hospital stay vs ODP. Collectively the data strongly
suggest that MIDP may be superior to ODP with regard to
perioperative outcomes including blood loss, complications, and
length‐of‐stay.
The current study showed a widespread and increased utilization
of MIDP for pNET among major centers in the United States. In
addition to the overall increase in the utilization of MIDP, the
conversion rate decreased roughly from 20.0% before 2008 to 7.8%
in 2009‐2012 and 7.6% in 2013‐2016. Braga et al25 noted an overall
conversion rate of 23.3%, yet noted that the conversion rate dropped
significantly after the first ten laparoscopic DP cases. In contrast,
Shakir et al26 noted that robotic DP required 40 cases to optimize
outcomes, such as operative time and blood loss. Interestingly, a
temporal trend in the number of lymph nodes evaluated also
increased over the time periods examined, whereas the incidence
of severe complications and length‐of‐stay also both decreased.
These data indicated that the increased use of MIDP over time has
paralleled an increase in experience that has further augmented the
beneficial perioperative effects of the minimally invasive approach.
While the favorable perioperative outcomes associated with
MIDP have been generally accepted, the oncologic outcomes of
MIDP vs ODP for pNET remain undetermined. Most previous reports
reported only small groups of patients and data on surgical factors
(eg margin status, lymphadenectomy) were not well defined. The data
from our multi‐institutional series demonstrated that some oncologic
and surgical factors were comparable among patients who under-
went MIDP vs ODP, yet other factors varied. For example, patients
who underwent MIDP had a higher rate of R0 resection, which was
likely because of patients with ODP presenting with more advanced
disease (Table 1). The data did suggest, however, that MIDP was at
least as effective as ODP in obtaining an adequate margin and lymph
node evaluation. Patients who underwent ODP had a higher risk of
recurrence that was almost undoubtedly related to differences in
underlying tumor factors. To minimize the patient selection bias, we
utilized PSM to create more balanced cohorts for comparison. On
PSM, after balancing many tumor and surgical factors, patients who
underwent MIDP still had a lower incidence of tumor recurrence, yet
OS was equivalent to patients who underwent ODP. In a separate
study by Xourafas et al,24 patients undergoing MIDP (n = 78) for
pNET similarly had comparable recurrence and OS vs individuals who
underwent ODP. Interestingly, the incidence of recurrence after
MIDP was similar in the current study compared with the data from
Xourafas et al24 (3.7% vs 4%), yet recurrence among the ODP group
was considerably higher in the current study (19.1% vs 4%). The
difference in recurrence was undoubtedly multifactorial and was
TABLE 3 Factors associated with tumor recurrence after curative
resection of pancreatic neuroendocrine tumors (pNETs)
Univariate analysis Multivariable analysis
HR (95% CI) P value
HR
(95% CI) P value
Functional status 0.737
Nonfunctional Ref.
Functional 0.7 (0.1‐5.1)
Genetic syndrome 0.017 0.034
Not associated Ref. Ref
Associated 1.9 (1.1‐3.3) 2.5 (1.1‐5.8)
Symptomatic 0.016 0.701
No Ref. Ref.
Yes 1.8 (1.1‐2.8) 1.1 (0.6‐2.3)
Surgery technique <0.001 0.033
Open Ref. Ref.
Laparoscopic/
robotic
0.2 (0.1‐0.5) 0.3 (0.1‐0.9)
Major vascular
resection
5.0
(2.0‐12.5)
0.001 2.0 (0.5‐7.3) 0.321
Splenectomy 2.2 (1.1‐4.8) 0.046 1.5 (0.4‐5.6) 0.527
Tumor size, cm <0.001 0.005
≤3 Ref. Ref.
>3 5.6 (3.4‐9.3) 3.3 (1.4‐7.4)
Multiple lesions 1.0 (0.5‐1.9) 0.966
Surgical margin 0.009 0.389
R0 Ref. Ref.
R1 2.0 (1.2‐3.4) 1.5 (0.6‐3.5)
Tumor
differentiation
Well
differentiated
Ref. Ref.
Moderately
differentiated
2.0 (1.0‐3.8) 0.043 0.8 (0.3‐2.3) 0.655
Poorly
differentiated
8.1
(2.9‐22.6)
<0.001 3.8
(0.4‐33.4)
0.228
Nodal status <0.001 0.517
N0 Ref. Ref.
N1 2.8 (1.7‐4.4) 0.8 (0.3‐1.7)
WHO classification
G1 Ref. Ref.
G2 3.2 (1.8‐5.6) <0.001 2.1 (0.9‐4.8) 0.092
G3 12.8
(5.3‐30.5)
<0.001 4.1
(0.8‐20.7)
0.088
Lymph‐vascular
invasion
3.9 (2.3‐6.7) <0.001 1.5 (0.7‐3.5) 0.308
Perineural invasion 1.6 (0.9‐3.1) 0.139
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likely related to differences in patient selection. For example, the
incidence of R1 resection among patients undergoing ODP was
higher in the current study than the study by Xourafas et al24 (16.6%
vs 7%). Of note, similar to the current study, DiNorcia et al27
reported a higher tumor recurrence rate (15.3%) after open surgery
vs minimally invasive procedures (4.4%) for pNET. These authors
postulated that the higher recurrence rate in the open surgery group
was explained by more advanced disease on presentation.27 The data
from the current study, as well as several previous reports, strongly
suggest at least non‐inferior oncologic outcomes for MIDP vs ODP
for the resection of pNET.
The current study had several limitations. Although the multi‐
institutional collaboration increased the sample size and general-
izability of the results, possible inconsistency in patient selection,
choice of MIDP or ODP, surgical skills and procedures, pathologic
assessment and reporting, as well as postoperative surveillance
likely existed. While known tumor and surgery‐related factors
were matched between the MIDP and ODP groups using
PSM, patients undergoing ODP still had pNET with more
advanced tumor features vs MIDP in the matched cohort. Patients
with smaller and low‐grade tumor were more likely to undergo
MIS. As such, residual confounding‐by‐indication persisted in
comparing the MIDP vs ODP groups. Moreover, the outcome of
patients undergoing MIS is largely influenced by technical skills.
However, the number of surgeons in each institution and their
learning curves were not available in the current database. The
current study also focused on DP; future studies will, therefore,
need to assess the short‐ and long‐term outcomes of minimally
invasive vs open procedures for more complex surgery, such as
PD for pNET.
In conclusion, the utilization of MIDP increased to more than
one‐half of all surgical procedures for pNET over the last two
decades. Current conversion rates were less than 10% and MIDP
was associated with less blood loss, a lower incidence of post-
operative morbidity, and a shorter hospital stay compared with
ODP. The data from the current study demonstrated comparable
oncologic surgical metrics, as well as similar long‐term OS among
patients undergoing MIDP over ODP in the treatment of pNET. As
such, a minimally invasive approach to pNET tumors should be
considered as the surgical approach of choice when technically
feasible.
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